ARQ 761

Overview

ARQ 761 is an intravenously administered analogue of β-Lapachone, a naturally existing substance. ARQ 761 is a pro-drug of ARQ 501 and has demonstrated in vitro activity against a wide range of solid tumors. In Phase 1a testing with single agent ARQ 761, anti-cancer activity as measured by tumor responses occurred exclusively in a portion of patients with high levels of NQO1.

Mechanism of Action

ARQ 761 is an NQO1 inhibitor, with the potential to enhance the effect of chemotherapy and other cancer therapies, which is over-expressed in many cancers.

Precision Medicine

Phase 1a testing with ARQ 761 identified anti-cancer activity, as measured by tumor responses, that occurred exclusively in a portion of the patient population with high levels of NQO1.

Diseases We Are Exploring in Clinical Trials

Oncology
NQO1 is over-expressed in many cancers. For instance, ~90% of pancreatic and NSCLC cancers express NQO1 10-100 fold, while ~60% of breast, prostate and colon cancers express NQO1 5-20 fold. NQO1, in combination with chemotherapy or PARP inhibitors, has shown efficacy in multiple cancer lines.

Current Clinical Trials

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300